KR102788997B1 - Lpa 길항제로서의 옥사비시클로 산 - Google Patents

Lpa 길항제로서의 옥사비시클로 산 Download PDF

Info

Publication number
KR102788997B1
KR102788997B1 KR1020217011085A KR20217011085A KR102788997B1 KR 102788997 B1 KR102788997 B1 KR 102788997B1 KR 1020217011085 A KR1020217011085 A KR 1020217011085A KR 20217011085 A KR20217011085 A KR 20217011085A KR 102788997 B1 KR102788997 B1 KR 102788997B1
Authority
KR
South Korea
Prior art keywords
lpa
mmol
alkyl
independently
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011085A
Other languages
English (en)
Korean (ko)
Other versions
KR20210060546A (ko
Inventor
피터 타이 와 쳉
준 시
시웨이 타오
하오 장
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20210060546A publication Critical patent/KR20210060546A/ko
Application granted granted Critical
Publication of KR102788997B1 publication Critical patent/KR102788997B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020217011085A 2018-09-18 2019-09-16 Lpa 길항제로서의 옥사비시클로 산 Active KR102788997B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732588P 2018-09-18 2018-09-18
US62/732,588 2018-09-18
PCT/US2019/051272 WO2020060914A1 (en) 2018-09-18 2019-09-16 Oxabicyclo acids as lpa antagonists

Publications (2)

Publication Number Publication Date
KR20210060546A KR20210060546A (ko) 2021-05-26
KR102788997B1 true KR102788997B1 (ko) 2025-03-28

Family

ID=68073221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011085A Active KR102788997B1 (ko) 2018-09-18 2019-09-16 Lpa 길항제로서의 옥사비시클로 산

Country Status (7)

Country Link
US (1) US12428430B2 (https=)
EP (1) EP3853232B1 (https=)
JP (1) JP7412424B2 (https=)
KR (1) KR102788997B1 (https=)
CN (1) CN113366000A (https=)
ES (1) ES2941774T3 (https=)
WO (1) WO2020060914A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220041572A1 (en) * 2018-09-18 2022-02-10 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
KR101875246B1 (ko) 2010-12-07 2018-07-05 아미라 파마슈티칼스 인코포레이티드 폴리시클릭 lpa₁ 길항제 및 그의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390178C (zh) 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
EA201390821A1 (ru) 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
SG11201406526WA (en) 2012-04-27 2014-11-27 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
SG11201407228PA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
UA109868C2 (ru) 2012-06-20 2015-10-12 Ф. Хоффманн-Ля Рош Аг Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
CN111699180B (zh) 2017-12-19 2024-11-29 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
WO2019126089A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
EP3728209B1 (en) 2017-12-19 2025-12-24 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
EP4011875A1 (en) 2017-12-19 2022-06-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR102756639B1 (ko) 2017-12-19 2025-01-16 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112041302B (zh) 2017-12-19 2024-11-19 百时美施贵宝公司 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
US20220041572A1 (en) 2018-09-18 2022-02-10 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875246B1 (ko) 2010-12-07 2018-07-05 아미라 파마슈티칼스 인코포레이티드 폴리시클릭 lpa₁ 길항제 및 그의 용도
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

Also Published As

Publication number Publication date
JP7412424B2 (ja) 2024-01-12
WO2020060914A1 (en) 2020-03-26
EP3853232B1 (en) 2023-03-01
JP2022500473A (ja) 2022-01-04
EP3853232A1 (en) 2021-07-28
CN113366000A (zh) 2021-09-07
US20210317131A1 (en) 2021-10-14
US12428430B2 (en) 2025-09-30
KR20210060546A (ko) 2021-05-26
ES2941774T3 (es) 2023-05-25

Similar Documents

Publication Publication Date Title
KR102702231B1 (ko) Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산
KR102756637B1 (ko) Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
KR102756639B1 (ko) Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸
KR102828422B1 (ko) Lpa 길항제로서의 시클로헥실 산 이속사졸 아진
KR102697358B1 (ko) Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
KR102702229B1 (ko) Lpa 길항제로서의 트리아졸 n-연결된 카르바모일 시클로헥실 산
KR102698386B1 (ko) Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
KR102788997B1 (ko) Lpa 길항제로서의 옥사비시클로 산
KR102726939B1 (ko) Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
KR102725744B1 (ko) Lpa 길항제로서의 시클로헥실 산 피라졸 아진
KR102800284B1 (ko) Lpa 길항제로서의 시클로헵틸 산
KR102791678B1 (ko) Lpa 길항제로서의 시클로부틸 카르복실산
US12384768B2 (en) Isoxazole carboxylic acids as LPA antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210414

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220915

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240823

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250326

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250326

End annual number: 3

Start annual number: 1

PG1601 Publication of registration